Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults

Vaccine

Volumn 27, Issue 3, 2009, Pages 454-459

  Van Damme, Pierre ^a   Oosterhuis Kafeja, Froukje ^a   Van der Wielen, Marie ^a   Almagor, Yotam ^b   Sharon, Ofer ^b   Levin, Yotam ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b NANOPASS TECHNOLOGIES LTD   (Israel)

Author keywords

Adults; Device; Dose sparing; Flu vaccine; Microneedle

Indexed keywords

ALPHA-RIX; HEMAGGLUTININ; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DRUG EFFICACY; DRUG SAFETY; ECCHYMOSIS; FEMALE; GEOMETRIC MEAN TITER; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INJECTION PAIN; INJECTION SITE DESQUAMATION; INJECTION SITE DISCOLORATION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LOW DRUG DOSE; MALAISE; MALE; MICRONEEDLE DEVICE; MYALGIA; NEEDLE; PARAMETER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SEROCONVERSION; SINGLE BLIND PROCEDURE; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; EQUIPMENT AND SUPPLIES; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; MALE; PROSPECTIVE STUDIES; VACCINATION; YOUNG ADULT;

EID: 57649210646     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.10.077     Document Type: Article

References (42)

1. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 292 (2004) 1333-1340
2. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N.J., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 (2003) 179-186
3. Nichol K.L., Nordin J.D., Nelson D.B., Mullooly J.P., and Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 357 (2007) 1373-1381
4. MMWR Morb Mortal Wkly Rep 2007;56(37):953-9 (September 21).
5. Halperin S.A., Smith B., Mabrouk T., Germain M., Trépanier P., Hassell T., et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 20 7-8 (2002) 1240-1247
6. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Krieg A.M., Li Y., et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22 23-24 (2004) 3136-3143
7. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 9587 (2007) 580-589
8. Nichol K.L., and Treanor J.J. Vaccines for seasonal and pandemic influenza. J Infect Dis 194 (2006) S111-S118
9. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., and Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351 (2004) 2295-2301
10. Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351 (2004) 2286-2294
11. Alarcon J.B., Hartley A.W., Harvey N.G., and Mikszta J.A. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin Vaccine Immunol 14 (2007) 375-381
12. Mikszta J.A., Sullivan V.J., Dean C., Waterson A.M., Alarcon J.B., Dekker III J.P., et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J Infect Dis 191 (2005) 278-288
13. Dean C.H., Alarcon J.B., Waterston A.M., Draper K., Early R., Guirakhoo F., et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese Encephalitis (ChimeriVax-JE) in non-human primates. Hum Vaccine 1 (2005) 6-11
14. Mikszta J.A., Dekker III J.P., Harvey N.G., Harvey G., Dean C.H., Britiingham J.M., et al. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect Immun 74 (2006) 6806-6810
15. Auewarakul P., Kositanont U., Sornsathapornkul P., Tothong P., Kanyok R., and Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 25 4 (2007) 659-663 (Epub 2006 September 1)
16. Weniger B.G. Intradermal vaccination as a dose-sparing strategy in routine and emergency campaigns, Steering Committee-new vaccine delivery systems. Initiative for vaccine research 20-22 (2006 Sep), World Health Organization, Geneva
17. Belshe R.B., Newman F.K., Wilkins K., Graham I.L., Babusis E., Ewell M., et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25 37-38 (2007) 6755-6763
18. The National Institute of Health (NIH) registry of federally and privately supported clinical trials [homepage on the Internet]. Search results for "intradermal + vaccine"; [search performed on 2008 May 20] Available from: http://clinicaltrials.gov/ct2/results?term=intradermal+vaccine.
19. La Montagne J.R., and Fauci A.S. Intradermal influenza vaccination-can less be more?. N Engl J Med 351 (2004) 2230-2232
20. Chau K.F., Cheng Y.L., Tsang D.N.C., Choi K.S., Wong K.M., Chak W.L., et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: a comparison with the intramuscular vaccination. Am J Kidney Dis 43 (2004) 910-917
21. Chiu S.S., Peiris J.S.M., Chan Kwok H., Sang Wong W.H., and Lau Y.L. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 119 (2007) 1076-1082
22. Bos Jan D. Skin immune system-cutaneous immunology and clinical immunodermatology. 3rd ed. (2005), CRC Press
23. Flynn P.M., Shenep J.L., Mao L., Crawford R., Williams B.F., and Williams B.G. Influence of needle gauge in Mantoux skin testing. Chest 106 (1994) 1463-1465
24. Tarnow K., and King N. Intradermal injections: traditional bevel up versus bevel down. Appl Nurs Res 17 4 (2004) 275-282
25. Lee Y., and Hwang K. Skin thickness of Korean adults. Surg Radiol Anat 24 (2002) 183-189
26. Laurent A., Mistretta F., Bottigioli D., Dahel K., Goujon C., Nicolas J.F., et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine 25 34 (2007) 6423-6430
27. Razzell P.E., and Edward Jenner. The history of a medical myth. Med Hist 9 July (1965) 216-229
28. Tuft L. The skin as an immunological organ with results of experimental investigations and review of the literature. J Immunol 21 (1931) 85-100
29. Francis Jr. T., and Magill T.P. The antibody response of human subjects vaccinated with the virus of human influenza. J Exp Med 65 (1937) 251-259
30. Salisbury D.M., and Begg N.T. Tuberculosis: BCG immunization. Immunization against infectious disease (1996), Her Majesty's Stationery Office, London p. 219-41
31. Braddick M.R. Intradermal hepatitis B vaccine. Lancet 1 (1989) 957-958
32. Redfield R.R., Innis B.L., Scott R.M., Cannon H.G., and Bancroft W.H. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine-a cost reduction strategy. JAMA 254 (1985) 3203-3206
33. Wistrom J. Intramuscular vs. intradermal hepatitis B vaccination: a 6-year follow-up. JAMA 273 (1995) 1835-1836
34. Pancharoen C., Mekmullica J., Thisyakorn U., Kasempimolporn S., Wilde H., and Herzog C. Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs. Clin Infect Dis 41 (2005) 1537-1540
35. Kamoltham T., Khawplod P., and Wilde H. Rabies intradermal post-exposure vaccination of humans using reconstituted and stored vaccine. Vaccine 20 (2002) 3272-3276
36. Khawplod P., Wilde H., Sirikwin S., Benjawongkulchai M., Limusanno S., Jaijaroensab W., et al. Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection. Vaccine 24 (2006) 3084-3086
37. Baxby D. Smallpox vaccination techniques; from knives and forks to needles and pins. Vaccine 20 16 (2002) 2140-2149
38. The European Clinical Trials Database (EudraCT) [homepage on the Internet]. Available from: http://eudract.emea.europa.eu/.
39. The National Institute of Health (NIH) registry of federally and privately supported clinical trials (ClinicalTrials.gov) [homepage on the Internet]. Available from: http://clinicaltrials.gov.
40. CPMP note for guidance on harmonization of requirements for influenza vaccines. London: The European Agency for the Evaluation of Medicinal Products; 1997. p. 1-18 (CPMP/BWP/214/96).
41. Center for Disease Control (CDC). 2007-08 Recommendations of the Advisory Committee on Immunization Practices (ACIP).
42. Leroux-Roels I, Leroux-Roels G, Holland D, Booy R, Weber F, Saville M. Intradermal influenza vaccination offers superior immunogenicity compared with conventional vaccine in the elderly, and is safe after two annual vaccinations in adults. In: Proceedings of the International Society of Developmental and Comparative Immunology (ISDCI) 1st vaccine congress. Amsterdam; December 2007.